(Q42992965)

12 November 2017

title

25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. (English)

1 reference

12 November 2017

0 references

1 reference

1 reference

1 reference

1

1 reference

12 November 2017

publication date

7 June 2013

1 reference

Nature Reviews Immunology

12 November 2017

published in

1 reference

12 November 2017

volume

13

1 reference

12 November 2017

issue

7

1 reference

12 November 2017

page(s)

535-542

1 reference

https://scigraph.springernature.com/pub.10.1038/nri3463

12 November 2017

exact match

0 references

cites work

Global epidemiology of hepatitis C virus infection

1 reference

DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection

21 January 2018

1 reference

Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease

21 January 2018

1 reference

Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C.

21 January 2018

1 reference

Hepatitis C virus infection

21 January 2018

1 reference

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

21 January 2018

1 reference

Replication of hepatitis C virus

21 January 2018

1 reference

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

21 January 2018

1 reference

Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance

21 January 2018

1 reference

Nomenclature and numbering of the hepatitis C virus

21 January 2018

1 reference

21 January 2018

Innate immunity and HCV.

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

Alpha Interferon Induces Long-Lasting Refractoriness of JAK-STAT Signaling in the Mouse Liver through Induction of USP18/UBP43

21 January 2018

1 reference

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

21 January 2018

1 reference

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus

21 January 2018

1 reference

Virus interference. I. The interferon

21 January 2018

1 reference

The interferons: 50 years after their discovery, there is much more to learn

21 January 2018

1 reference

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

21 January 2018

1 reference

Complex modulation of cell type-specific signaling in response to type I interferons

21 January 2018

1 reference

Type I interferons in host defense

21 January 2018

1 reference

Interferon-inducible antiviral effectors

21 January 2018

1 reference

Distinct induction patterns and functions of two closely related interferon-inducible human genes, ISG54 and ISG56

21 January 2018

1 reference

A diverse range of gene products are effectors of the type I interferon antiviral response

21 January 2018

1 reference

Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication.

21 January 2018

1 reference

IFITM1 is a tight junction protein that inhibits hepatitis C virus entry

21 January 2018

1 reference

IFITM3 restricts the morbidity and mortality associated with influenza

21 January 2018

1 reference

Interferon signaling and treatment outcome in chronic hepatitis C

21 January 2018

1 reference

Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon alpha/beta

21 January 2018

1 reference

Distinct requirements for IFNs and STAT1 in NK cell function

21 January 2018

1 reference

Cutting Edge: The direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection

21 January 2018

1 reference

Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection

21 January 2018

1 reference

CD8 T cells specific for lymphocytic choriomeningitis virus require type I IFN receptor for clonal expansion

21 January 2018

1 reference

Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection

21 January 2018

1 reference

HCV Persistence and Immune Evasion in the Absence of Memory T Cell Help

21 January 2018

1 reference

Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.

21 January 2018

1 reference

Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.

21 January 2018

1 reference

The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection

21 January 2018

1 reference

CD4+ T cell responses in patients with chronic hepatitis C undergoing peginterferon/ribavirin therapy correlate with faster, but not sustained, viral clearance

21 January 2018

1 reference

HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).

21 January 2018

1 reference

Human leukocyte interferon produced by E. coli is biologically active

21 January 2018

1 reference

Synthesis in E. coli of a polypeptide with human leukocyte interferon activity

21 January 2018

1 reference

Antiviral Treatment of Chronic Hepatitis B Virus Infection. I. Changes in Viral Markers with Interferon Combined with Adenine Arabinoside

21 January 2018

1 reference

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

21 January 2018

1 reference

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

21 January 2018

1 reference

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

21 January 2018

1 reference

A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis

21 January 2018

1 reference

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

21 January 2018

1 reference

Ribavirin treatment for chronic hepatitis C

21 January 2018

1 reference

A pilot study of ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

21 January 2018

1 reference

Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone

21 January 2018

1 reference

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

21 January 2018

1 reference

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

Mechanism of action of interferon and ribavirin in treatment of hepatitis C

21 January 2018

1 reference

Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action

21 January 2018

1 reference

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

Interferon-β and interferon-λ signaling is not affected by interferon-induced refractoriness to interferon-α in vivo

21 January 2018

1 reference

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents

21 January 2018

1 reference

Antiviral strategies in hepatitis C virus infection

21 January 2018

1 reference

Preliminary study of two antiviral agents for hepatitis C genotype 1.

21 January 2018

1 reference

Nonlinear partial differential equations and applications: Genomic analysis of the host response to hepatitis C virus infection

21 January 2018

1 reference

Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees

21 January 2018

1 reference

Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus

21 January 2018

1 reference

Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation

21 January 2018

1 reference

Cellular immune selection with hepatitis C virus persistence in humans

21 January 2018

1 reference

The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes

21 January 2018

1 reference

Immune evasion versus recovery after acute hepatitis C virus infection from a shared source

21 January 2018

1 reference

PD-1 Expression in Acute Hepatitis C Virus (HCV) Infection Is Associated with HCV-Specific CD8 Exhaustion

21 January 2018

1 reference

Success and failure of virus-specific T cell responses in hepatitis C virus infection

21 January 2018

1 reference

Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.

21 January 2018

1 reference

Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C.

21 January 2018

1 reference

Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response

21 January 2018

1 reference

Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C.

21 January 2018

1 reference

Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

21 January 2018

1 reference

IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.

21 January 2018

1 reference

Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system

21 January 2018

1 reference

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

21 January 2018

1 reference

Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection

21 January 2018

1 reference

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

21 January 2018

1 reference

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

Evasion of intracellular host defence by hepatitis C virus

21 January 2018

1 reference

Failure of innate and adaptive immune responses in controlling hepatitis C virus infection

21 January 2018

1 reference

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex

21 January 2018

1 reference

IL-28, IL-29 and their class II cytokine receptor IL-28R

21 January 2018

1 reference

Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.

21 January 2018

1 reference

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

21 January 2018

1 reference

Clinical and serological analysis of transfusion-associated hepatitis

21 January 2018

1 reference

Transfusion-Associated Hepatitis Not Due to Viral Hepatitis Type A or B

21 January 2018

1 reference

Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide

21 January 2018

1 reference

21 January 2018

1 reference

Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site

21 January 2018

1 reference

Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase

21 January 2018

1 reference

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

21 January 2018

1 reference

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

21 January 2018

1 reference

Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection

31 March 2020

1 reference

Double-blind study of leucocyte interferon administration in chronic HBsAg-positive hepatitis

31 March 2020

1 reference

Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group

31 March 2020

1 reference

Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23743475

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Transcriptional induction by interferon. New protein(s) determine the extent and length of the induction

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23743475

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRI3463

1 reference

Dimensions Publication ID

12 November 2017

1003031370

0 references

1 reference